Sidika Oztop

Sidika Oztop

Auto-generated profile, based on publicly available information

Sidika Oztop

Department of Medical Biology, Faculty of Medicine, Ankara Medipol University, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2022 in ACS Infectious Diseases
Verified
Journal Article
Open access
RARecep E. Ahan
Recep E. Ahan
AHAlireza Hanifehnezhad
Alireza Hanifehnezhad
EKEbru Ş. Kehribar
Ebru Ş. Kehribar
TOTuba C. Oguzoglu
Tuba C. Oguzoglu
KFKatalin Földes
Katalin Földes
USUrartu Seker
Urartu Seker
The COVID-19 (coronavirus disease-19) pandemic affected more than 180 million people around the globe, causing more than five million deaths as of January 2022. SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the new coronavirus, has been identified as the primary cause of the infection. The number of vaccinated people is increasing; however, prophylactic drugs are highly demanded to ensure secure social contact. A number of drug molecules have been repurposed to fight against SARS-CoV-2, and some of them have been proven to be effective in preventing hospitalization or ICU admissions. Here, we demonstrated griffithsin (GRFT), a lectin protein, to block the entry of SARS-CoV-2 and its variants, Delta and Omicron, into the Vero E6 cell lines and IFNAR(-/-) mouse models by attaching to the spike protein of SARS-CoV-2. Given the current mutation frequency of SARS-CoV-2, we believe that GRFT protein-based drugs will have a high impact in preventing the transmission of both the Wuhan strain as well as any other emerging variants, including Delta and Omicron variants, causing the high-speed spread of COVID-19.

1 September 2020 in Heliyon
Verified
Journal Article
Open access
AHAlireza Hanifehnezhad
Alireza Hanifehnezhad
EKEbru Şahin Kehribar
Ebru Şahin Kehribar
SÖSıdıka Öztop
Sıdıka Öztop
ASAli Sheraz
Ali Sheraz
SKSerkan Kasırga
Serkan Kasırga
AOAykut Ozkul
Aykut Ozkul
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently a global pandemic with unprecedented public health, economic and social impact. The development of effective mitigation strategies, therapeutics and vaccines relies on detailed genomic and biological characterization of the regional viruses. This study was carried out to isolate SARS-CoV-2 viruses circulating in Anatolia, and to investigate virus propagation in frequently-used cells and experimental animals. We obtained two SARS-CoV-2 viruses from nasopharngeal swabs of confirmed cases in Vero E6 cells, visualized the virions using atomic force and scanning electron microscopy and determined size distribution of the particles. Viral cytopathic effects on Vero E6 cells were initially observed at 72 h post-inoculation and reached 90% of the cells on the 5th day. The isolates displayed with similar infectivity titers, time course and infectious progeny yields. Genome sequencing revealed the viruses to be well-conserved, with less than 1% diversity compared to the prototype virus. The analysis of the viral genomes, along with the available 62 complete genomes from Anatolia, showed limited diversity (up to 0.2% on deduced amino acids) and no evidence of recombination. The most prominent sequence variation was observed on the spike protein, resulting in the substitution D614G, with a prevalence of 56.2%. The isolates produced non-fatal infection in the transgenic type I interferon knockout (IFNAR−/-) mice, with varying neutralizing antibody titers. Hyperemia, regional consolidation and subpleural air accumulation was observed on necropsy, with similar histopathological and immunohistochemistry findings in the lungs, heart, stomach, intestines, liver, spleen and kidneys. Peak viral loads were detected in the lungs, with virus RNA present in the kidneys, jejunum, liver, spleen and heart. In conclusion, we characterized two local isolates, investigated in vitro growth dynamics in Vero E6 cells and identified IFNAR−/− mice as a potential animal model for SARS-CoV-2 experiments.

2 February 2019 in Anticancer Research
Verified
Journal Article
Open access
PDF file
SÖSidika Öztop
Sidika Öztop
AIAynur Işik
Aynur Işik
GGGüneş Güner
Güneş Güner
HGHakan Gürdal
Hakan Gürdal
EKErdem Karabulut
Erdem Karabulut
AAAytekin Akyol
Aytekin Akyol
Background/Aim: The challenges of cololorectal cancer (CRC) management include prediction of outcome and drug response or chemoresistance. This study aimed at examining whether βIII-tubulin (TUBB3), present in various types of normal tissues and cancer, is a biomarker for the response of colorectal neoplasms to paclitaxel. Materials and Methods: Six tissue microarrays (TMAs) including 14 colon mucosa, 78 polyps and 202 CRCs were constructed. Assessment of TUBB3 expression was performed by immunohistochemistry, and it was scored as negative, focal and positive. In the HCT116 cell line, TUBB3 expression was silenced with siRNA. Paclitaxel toxicity was evaluated in TUBB3-silenced and control HCT116 cell lines. Results: The non-neoplastic colon mucosa was negative for TUBB3, while some of colon adenomas and CRCs expressed TUBB3 in various levels from focal to diffuse. TUBB3-expressing CRCs tended to have poor prognosis and silencing of TUBB3 sensitized the cells to paclitaxel. Conclusion: TUBB3 was expressed in a subgroup of colorectal neoplasms. Suppression of TUBB3 potentialy sensitizes neoplastic cells to taxanes.

22 January 2025 in EMBO Molecular Medicine
Verified
Journal Article
Open access
HBHatoon Baazim
Hatoon Baazim
EKEmre Koyuncu
Emre Koyuncu
GTGürol Tuncman
Gürol Tuncman
MBM Furkan Burak
M Furkan Burak
LMLea Merkel
Lea Merkel
GHGökhan S Hotamisligil
Gökhan S Hotamisligil
Host metabolic fitness is a critical determinant of infectious disease outcomes. Obesity, aging, and other related metabolic disorders are recognized as high-risk disease modifiers for respiratory infections, including coronavirus infections, though the underlying mechanisms remain unknown. Our study highlights fatty acid-binding protein 4 (FABP4), a key regulator of metabolic dysfunction and inflammation, as a modulator of SARS-CoV-2 pathogenesis, correlating strongly with disease severity in COVID-19 patients. We demonstrate that loss of FABP4 function, by genetic or pharmacological means, reduces SARS-CoV-2 replication and disrupts the formation of viral replication organelles in adipocytes and airway epithelial cells. Importantly, FABP4 inhibitor treatment of infected hamsters diminished lung viral titers, alleviated lung damage and reduced collagen deposition. These findings highlight the therapeutic potential of targeting host metabolism in limiting coronavirus replication and mitigating the pathogenesis of infection.

21 February 2022 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
MUMeral Uner
Meral Uner
AIAynur Isık
Aynur Isık
SOSıdıka Oztop
Sıdıka Oztop
EKErdem Karabulut
Erdem Karabulut
SCSecil Demirkol Canlı
Secil Demirkol Canlı
AAAytekin Akyol
Aytekin Akyol
Gastric carcinomas consist of a heterogeneous group of neoplasms with broad cytological and architectural variations. Gastric carcinomas with lymphoid stroma show poor correlation between their histomorphology and biological behavior. This contrast causes a need for more detailed analysis and molecular exploration of lymphoid stroma-rich gastric carcinomas with medullary like features and lack of glandular differentiation. In this study, we performed a detailed retrospective analysis of 53 gastric carcinomas among 654 gastric tumors from surgical resection specimens, all of which had no prominent glandular differentiation. Morphological and clinical data were compared with immunohistochemistry (MLH1, PMS2, MSH2 and MSH6 for mismatch repair mechanism deficiency; CD2, CD8 and CD163 for immune infiltration; and PD-1, PD-L1, LMP-1, ERBB2 and ki-67) besides EBER in situ hybridization and molecular studies (PCR based microsatellite instability and BRAF V600E mutation analysis). Morphological, immunohistochemical and molecular findings lead us to classify lymphoid stroma–rich advanced gastric carcinomas (n = 40/53) into two distinct entities originating from two different pathogenetic pathway: one is gastric carcinomas revealing predominantly medullary type morphology with defective DNA mismatch repair mechanism (n = 30/53) and the other is EBV associated carcinomas (n = 10/53). In addition, we suggest that biomarker based classification algorithms besides morphological evaluation are necessary to identify these two entities. Distinguishing these entities is crucial to apply different treatment strategies, including alternative treatments such as immunotherapy.

11 September 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AHAlireza Hanifehnezhad
Alireza Hanifehnezhad
SOSidika Oztop
Sidika Oztop
ETEce Tavukcuoglu
Ece Tavukcuoglu
YTYigit Tanyeri
Yigit Tanyeri
EYEkimcan Yoyler
Ekimcan Yoyler
AOAykut Ozkul
Aykut Ozkul
Platforms based on adenoviral vectors have proven their efficiency in developing vaccines and therefore can be considered potential candidates for immunization strategies against CCHFV. In this study, four replication-deficient recombinant human adenovirus serotype 5 (AdV5) vectors were engineered to express CCHFV antigens: a dual-antigen NP-P2A-Gc construct and monocistronic constructs for nucleoprotein (NP), glycoprotein complex precursor (GPC), and mature glycoprotein (Gc). Following GMP-compatible production and purification, vaccine candidates were evaluated in BALB/c mice (n = 4 per group) for immunogenicity and in IFNAR−/− mice (n = 4 per group) for protective efficacy using antigenically homologous or heterologous prime-boost regimens. Animals received priming immunization on day 0 and booster on day 28 followed by lethal CCHFV challenge (1000 TCID50) on day 42. Immune responses were characterized via ELISA, virus neutralization tests, cytokine profiling, ELISpot, and flow cytometry. Post-challenge survival, viral loads in target organs, and safety profiles were assessed. All AdV5 constructs successfully expressed the target antigens and induced rapid seroconversion, with 75–100% of animals exhibiting antibody responses after priming with a single dose. The dual-antigen formulations elicited the strongest Th1-polarized responses particularly nucleoprotein + Gc combinations with interferon-γ production more than 30-fold above baseline and preferential expansion of CD4+ T helper cells (60–70% of CD3+ populations). Neutralizing antibody titers varied across groups (80–160 arbitrary units in high responders) but did not directly correlate with survival outcomes. After lethal challenge, multiple vaccine formulations achieved 100% survival throughout the 10-day observation period, while only control groups showed no protection. All vaccinated animals demonstrated significant viral load reduction of two to four logs in liver and spleen tissues, with some achieving complete clearance of the virus. Furthermore, no off-target vector dissemination was detected in examined tissues confirming safety profile of the constructs. Immunization with adenovirus serotype 5 (AdV5) vectors expressing CCHFV antigens elicited potent humoral and cellular immune responses, conferring 100% protection against lethal viral challenge across the majority of evaluated formulations. Sterilizing immunity was observed in some animals, along with evidence that protection operates through multiple immune mechanisms including both neutralizing and non-neutralizing antibody-mediated pathways. These results strongly support further clinical development of AdV5-based CCHFV vaccines, with multiple formulation strategies showing high efficacy and providing flexibility for clinical advancement. GMP-compatible production methods have been successfully implemented for these candidates, supporting their advancement toward non-human primate studies and Phase I clinical trials.